Emergent Biosolutions
EBS
134 hedge funds and large institutions have $98.2M invested in Emergent Biosolutions in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 44 reducing their positions, and 46 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 44
0.65% less ownership
Funds ownership: 79.49% → 78.84% (-0.65%)
15% less call options, than puts
Call options by funds: $443K | Put options by funds: $520K
17% less funds holding
Funds holding: 161 → 134 (-27)
30% less capital invested
Capital invested by funds: $141M → $98.2M (-$42.6M)
57% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$3.09M |
| 2 |
BlackRock
New York
|
+$2.26M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.53M |
| 4 |
Morgan Stanley
New York
|
+$1.47M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.69M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.65M |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$1.84M |
| 4 |
Squarepoint
New York
|
-$1.19M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$936K |
EBS Hedge Fund Activity: Q4 2023 in Review
134 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2023, worth a combined $98.2M — down 30% from $141M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of EBS and 20 opened new positions — a net loss of 26 holders — while 44 trimmed existing stakes and 45 added.
The largest buyer was Charles Schwab, adding an estimated $3.09M. The largest seller was Millennium Management, cutting an estimated $3.69M.
- 134 institutional investors held Emergent Biosolutions (EBS) as of Q4 2023, down from 161 in Q3 2023.
- Funds reported $98.2M of Emergent Biosolutions stock for Q4 2023, down 30% quarter-over-quarter.
- 20 funds opened new Emergent Biosolutions positions in Q4 2023 and 46 closed out, a net change of -26 holders.
- The largest Emergent Biosolutions buyer in Q4 2023 was Charles Schwab, an estimated $3.09M added.
- The largest Emergent Biosolutions seller in Q4 2023 was Millennium Management, an estimated $3.69M sold.
Based on aggregated 13F filings for Q4 2023.